Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2016-07-27
Original market date: See footnote 1
2016-07-27
Product name:
SANDOZ MOMETASONE
Description:
SUSPENSION
DIN:
02449811
Product Monograph/Veterinary Labelling:
Date:
2022-07-29
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
SANDOZ CANADA INCORPORATED
110 Rue De Lauzon
Boucherville
Quebec
Canada
J4B 1E6
Class:
Human
Dosage form(s):
Spray, Metered Dose
Route(s) of administration:
Nasal
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
52:08.08
Anatomical Therapeutic Chemical (ATC): See footnote 4
R01AD09 MOMETASONE
Active ingredient group (AIG) number:See footnote5
0121732002
| Active ingredient(s) | Strength |
|---|---|
| MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE) | 50 MCG / ACT |